Testosterone Replacement Therapy (TRT) is FDA-approved for treating male hypogonadism (low testosterone) caused by testicular failure or hypothalamic-pituita...

Mechanism of Action

Mechanism of Action: TRT (Testosterone Replacement Therapy)

Androgen Receptor Signaling

Testosterone (T) and dihydrotestosterone (DHT) are the primary ligands for the androgen receptor (AR). Upon binding, the AR sheds heat shock proteins (HSP70, HSP90), dimerizes, and translocates to the nucleus where it binds androgen response elements (AREs). This genomic mechanism controls transcription of hundreds of target genes regulating anabolism, differentiation, and metabolic processes.

Non-Genomic Rapid Effects

Testosterone also exerts rapid, non-genomic effects through membrane-associated receptors and second messenger systems. These include activation of MAPK/ERK pathways, calcium influx through ion channels, and rapid nitric oxide production via eNOS activation—effects that occur within minutes, too fast for transcriptional regulation.

Musculoskeletal Anabolism

In skeletal muscle, testosterone activates the Akt/mTOR pathway, promoting protein synthesis while simultaneously inhibiting protein degradation through suppression of the ubiquitin-proteasome pathway. Testosterone also increases satellite cell number and activity, supporting muscle regeneration. In bone, AR signaling in osteoblasts stimulates bone formation while suppressing osteoclast activity, maintaining bone mineral density.

Metabolic Effects

Testosterone improves insulin sensitivity by enhancing GLUT4 expression and glucose uptake in muscle. It promotes lipolysis in adipose tissue through upregulation of hormone-sensitive lipase and beta-adrenergic receptor density, contributing to reductions in visceral fat mass.

Hematological Effects

TRT increases erythropoiesis through two mechanisms: stimulation of renal EPO secretion and direct action on bone marrow erythroid precursors via AR activation. This increases hemoglobin and hematocrit, which requires monitoring to avoid polycythemia.

HPG Axis Suppression

Exogenous testosterone suppresses the hypothalamic-pituitary axis through negative feedback. Reduced GnRH pulse frequency leads to decreased LH and FSH, resulting in testicular atrophy and oligospermia or azoospermia—a key consideration for fertility preservation.

Safety Profile

Safety Profile: TRT (Testosterone Replacement Therapy)

Common Side Effects

• Acne and oily skin (androgen-stimulated sebaceous glands)
• Fluid retention and weight gain
• Erythrocytosis/polycythemia (increased red blood cell count—the most common clinically significant side effect)
• Injection site pain, nodules, and irritation (injectable forms); skin irritation (topical gels/patches)
• Mood changes: irritability, aggression, or emotional lability
• Gynecomastia (estrogen conversion via aromatase)
• Testicular atrophy and reduced sperm count (suppression of endogenous gonadotropins)
• Increased body hair growth

Serious Adverse Effects

• Polycythemia: Hematocrit >54% increases stroke, DVT, and pulmonary embolism risk; most dangerous side effect requiring regular monitoring
• Cardiovascular risk: FDA-required label warning for increased risk of heart attack and stroke; TRAVERSE trial (2023) showed no excess MACE in men with CV risk factors, though ongoing monitoring advised
• Hepatotoxicity: Primarily with oral 17-alpha-alkylated androgens (methyltestosterone); injectable and transdermal forms carry minimal hepatic risk
• Sleep apnea: Worsening or new-onset obstructive sleep apnea
• Prostate effects: May accelerate growth of existing prostate cancer (does not cause de novo prostate cancer based on current evidence)
• Infertility: Suppresses spermatogenesis; may be irreversible in some men after prolonged use
• Venous thromboembolism

Contraindications

• Prostate cancer (active or suspected) or breast cancer in men
• Hematocrit > 50% at baseline
• Severe untreated obstructive sleep apnea
• Uncontrolled heart failure (NYHA class III–IV)
• Desire for fertility within 6–12 months (use hCG or clomiphene alternatives)
• Pregnancy (Category X; virilization of female fetus)
• Women (except specific off-label indications under specialist care)

Drug Interactions

• Anticoagulants (warfarin): Testosterone potentiates anticoagulation; INR monitoring required
• Insulin and oral hypoglycemics: Testosterone improves insulin sensitivity; dose reduction may be needed
• Corticosteroids: Additive fluid retention and edema
• 5-alpha reductase inhibitors (finasteride, dutasteride): May partially counteract androgenic effects (sometimes intentionally combined for hair loss)
• Aromatase inhibitors (anastrozole): Commonly co-prescribed to manage estradiol; not FDA-approved for this indication

Population-Specific Considerations

• Monitoring schedule: CBC/hematocrit, PSA, testosterone, estradiol, and lipids at 3, 6, and 12 months, then annually
• Hypogonadal men: Only prescribe for confirmed hypogonadism (two morning testosterone levels <300 ng/dL with symptoms)
• Cardiovascular patients: Individualized risk-benefit assessment; TRAVERSE trial provides some reassurance
• Fertility preservation: Use hCG or SERMs (clomiphene/enclomiphene) as alternatives when fertility desired
• Elderly (>65): Higher polycythemia risk; consider lower doses and more frequent monitoring
• Route selection: IM injections (most cost-effective), topical gels (steady levels), subcutaneous pellets (convenience), nasal (natesto—avoids first pass)
• Abuse potential: Schedule III controlled substance; supraphysiological doses carry substantially higher risks

Pharmacokinetic Profile